CLINICAL RESPONSE OF PATIENTS ON TOPICAL RUXOLITINIB FOR ACUTE AND CHRONIC GVHD

被引：0
|
作者：
Hudda, Zahra [1 ]
Flannery, Amanda [1 ]
Teusink-Cross, Ashley [1 ]
Khandelwal, Pooja [1 ]
机构：
[1] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA
来源：
PEDIATRIC BLOOD & CANCER | 2023年 / 70卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S203 / S204
页数：2
相关论文
共 50 条
  • [1] Topical Ruxolitinib for Chronic Cutaneous GvHD: Promising Results of a Phase 2 Clinical Trial
    Markova, Alina
    Papadopoulos, Esperanza B.
    Dusza, Stephen
    Ostojic, Jelena
    Ai, Rizi
    Maier, Tara
    Lacouture, Mario
    Tamari, Roni
    Gyurkocza, Boglarka
    Shaffer, Brian C.
    Scordo, Michael
    Perales, Miguel-Angel
    Harris, Andrew
    Ponce, Doris M.
    BLOOD, 2023, 142
  • [2] Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
    Hudda, Zahra
    Flannery, Amanda
    Teusink-Cross, Ashley
    Davies, Stella M.
    Khandelwal, Pooja
    BONE MARROW TRANSPLANTATION, 2024, 59 (03) : 425 - 427
  • [3] Topical ruxolitinib is promising as sole or adjunctive therapy in treating maculopapular rash of acute and chronic skin GVHD
    Zahra Hudda
    Amanda Flannery
    Ashley Teusink-Cross
    Stella M. Davies
    Pooja Khandelwal
    Bone Marrow Transplantation, 2024, 59 : 425 - 427
  • [4] Ruxolitinib approved for steroid-refractory acute and chronic GVHD
    不详
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2022, 49 (04) : 270 - 270
  • [5] Efficacy of Ruxolitinib in the management of chronic GVHD
    Giden, Asli Odabasi
    Erkurt, Mehmet Ali
    Hindilerden, Ipek Yonal
    Hidayet, Emine
    Berber, Ilhami
    Tiryaki, Tarik Onur
    Zorlu, Tugba
    Namdaroglu, Sinem
    Sarici, Ahmet
    Aksoy, Elif
    Yildizhan, Esra
    Aydin, Muruvvet Seda
    Korkmaz, Serdal
    Dal, Mehmet Sinan
    Ulas, Turgay
    Altuntas, Fevzi
    TRANSFUSION AND APHERESIS SCIENCE, 2025, 64 (01)
  • [6] Ruxolitinib in a Pediatric Patient with Chronic Gvhd
    Karras, Nicole
    Jung, Jae
    Cotliar, Jonathan
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S236 - S236
  • [7] The role of ruxolitinib in the management of acute GVHD
    Namdaroglu, Sinem
    Hidayet, Emine
    Aydin, Muruvvet Seda
    Erkurt, Mehmet Ali
    Berber, Ilhami
    Cinar, Olgu Erkin
    Ozet, Gulsum
    Yilmaz, Seda
    Apaydin, Merve
    Dal, Mehmet Sinan
    Korkmaz, Serdal
    Basturk, Abdulkadir
    Ulas, Turgay
    Altuntas, Fevzi
    TRANSFUSION AND APHERESIS SCIENCE, 2025, 64 (01)
  • [8] RUXOLITINIB IN CHRONIC GVHD BEYOND THIRD LINE TREATMENT: HIGH OVERALL RESPONSE RATE IN 18 PATIENTS
    Lupo-Stanghellini, M. T.
    Corti, C.
    Messina, C.
    Girlanda, S.
    Serpenti, F.
    Canzonieri, C.
    Pavesi, F.
    Marktel, S.
    Carrabba, M. G.
    Assanelli, A.
    Bernardi, M.
    Peccatori, J.
    Ciceri, F.
    HAEMATOLOGICA, 2019, 104 : 80 - 81
  • [9] Preliminary Experience with the use of Ruxolitinib, Ibrutinib or Imatinib for the Treatment of Acute or Chronic GVHD
    Secreto, Carolina
    Tonelli, Martina
    Busca, Alessandro
    Scaldaferri, Matilde
    Della Casa, Chiara
    Giaccone, Luisa
    Brunello, Lucia
    Butera, Sara
    Iovino, Giorgia
    Cattel, Francesco
    Bruno, Benedetto
    BONE MARROW TRANSPLANTATION, 2020, 55 (SUPPL 1) : 353 - 354
  • [10] Ruxolitinib for steroid-resistant acute GVHD
    Risitano, Antonio Maria
    de latour, Regis Peffault
    BLOOD, 2020, 135 (20) : 1721 - 1722
12345